<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254627</url>
  </required_header>
  <id_info>
    <org_study_id>GWICTIC-EMphase1</org_study_id>
    <secondary_id>CDMRP-PC16GW170044</secondary_id>
    <nct_id>NCT04254627</nct_id>
  </id_info>
  <brief_title>TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset</brief_title>
  <acronym>E/M</acronym>
  <official_title>Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness (GWI)-Associated Multi-symptom Disease Homeostasis Reset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Southeastern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rochester General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Southeastern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gulf War Illness is a condition that affects multiple major organ systems, resulting in a&#xD;
      diverse array of symptoms that include debilitating fatigue, memory and cognition&#xD;
      difficulties, headaches, sleep disturbances, gastrointestinal problems, skin rashes, and&#xD;
      musculoskeletal/joint pain. This phase I single-site, open-label two-arm study will assess&#xD;
      the safety and mechanistic efficacy of a sequential etanercept-mifepristone intervention for&#xD;
      Gulf War Illness. The results of this phase I study will be compared to those from an&#xD;
      existing short-duration study to identify the optimal duration and dosage for use in a future&#xD;
      phase II study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study in male Veterans 45-70 years of age who meet the modified Kansas and Centers&#xD;
      for Disease Control and Prevention (CDC) criteria for GWI (Gulf War Illness) and have high&#xD;
      physiologic stress. This phase I single-site, open-label, two-arm study will focus on&#xD;
      optimizing the dosage of a sequential etanercept-mifepristone intervention for GWI. Twenty&#xD;
      participants will be assessed at baseline, 6, 12, 13, 16 and 24 weeks. The investigators will&#xD;
      use systems biology methods to perform computational modelling of physiological responses to&#xD;
      supervised maximal exercise challenge studies on a fitness bicycle at baseline and 24 weeks.&#xD;
      These analyses will assess the impact of the treatment on homeostatic networks: the changes&#xD;
      in levels of physiological parameters and the changes in inter-correlations among the&#xD;
      measured parameters (e.g., cytokines), cross-sectionally and over time. Participants will&#xD;
      also undergo subjective assessments of functional health, symptom severity, pain, fatigue,&#xD;
      and cognition at baseline, 6, 12, 13, 16, and 24 weeks. Participants will be observed through&#xD;
      the treatment period and for 3 months after completion to assess immediate effects and&#xD;
      durability of the response.&#xD;
&#xD;
      The results of this phase I study will be compared to those from an existing short-duration&#xD;
      study to identify the optimal duration and dosage for use in a future phase II study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - incidence and severity of adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>Safety is assessed by the incidence and severity of adverse events, by relation to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanistic effects on biomarker relationships</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Mechanistic effects on biomarker network dynamics are measured by the change in median summary score for network-level distance between the Gulf War Illness biomarker profile at rest and model-predicted stable (healthy) states. These summary scores have a minimum value of zero and reflect the overall difference between the multidimensional relationships of the immune, autonomic, and neuroendocrine systems of ill participants at rest, relative to predicted values for stable (healthy) states. The analysis will be completed using the results of physical measures and biomarker assays performed on blood draws taken at rest prior to exercise challenges at baseline and 16 weeks. These include a Gulf War Illness-specific nanostring gene expression platform, an 18-multiplex cytokine assay, flow cytometry, neuropeptide, sex and stress hormone panels, and physical autonomic measures. Decreases in summary scores between baseline and 24 weeks indicate a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Homeostatic network correction</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The degree of correction of the homeostatic network toward normal is measured by the median summary score for network-level differences in connectivity of biomarker networks at multiple times during dynamic exercise challenges. These summary scores have a minimum value of zero and reflect overall changes within the immune, autonomic, and neuroendocrine systems during exercise, relative to predicted values for stable (healthy) states. The analysis will use the results of physical measures and blood draws taken before, during, and after exercise challenges at baseline and 24 weeks. The biomarker assays and physical measures include a Gulf War Illness-specific nanostring gene expression platform, an 18-multiplex cytokine assay, flow cytometry, neuropeptide, sex and stress hormone panels, and physical autonomic measures at multiple times during each exercise challenge and 24 hours afterward. Decreases in summary scores between baseline and 16 weeks indicate a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gulf War Illness</condition>
  <arm_group>
    <arm_group_label>Mifepristone 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 1 will receive one week of mifepristone at 300 mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 2 will receive one week of mifepristone at 600 mg (2x300 mg) daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept 50 mg weekly injection</description>
    <arm_group_label>Mifepristone 300 mg</arm_group_label>
    <arm_group_label>Mifepristone 600 mg</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Mifepristone 300 mg pill</description>
    <arm_group_label>Mifepristone 300 mg</arm_group_label>
    <arm_group_label>Mifepristone 600 mg</arm_group_label>
    <other_name>Mifeprex</other_name>
    <other_name>RU-486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  45-70 years old&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  In good health by medical history prior to 1990&#xD;
&#xD;
          -  Davidson Trauma scale score of 50 or higher&#xD;
&#xD;
          -  Meets modified Kansas and CDC case definition criteria for Gulf War Illness. The&#xD;
             modified Kansas definition, which includes the CDC criteria, includes the following:&#xD;
&#xD;
               1. Fatigue after exercise as predominant component (a history of exercise&#xD;
                  intolerance or exercise-induced worsening of symptoms)&#xD;
&#xD;
               2. Allowance for normal illnesses of aging, such as hypertension and diabetes, if&#xD;
                  the conditions are treated and are in demonstrable stable and normal ranges at&#xD;
                  the time of screening and assessment&#xD;
&#xD;
               3. Allowance of stable comorbid conditions such as PTSD (post traumatic stress&#xD;
                  disorder), MDD (major depressive disorder), and TBI (traumatic brain injury) that&#xD;
                  have not required hospitalization in the 5 years prior to recruitment. Severe TBI&#xD;
                  is excluded.&#xD;
&#xD;
          -  Able to provide consent to study&#xD;
&#xD;
          -  Protective titers for influenza and pneumococcal pneumonia, or updated vaccination for&#xD;
             these infections&#xD;
&#xD;
          -  Patients of childbearing potential must practice effective contraception during the&#xD;
             study, and be willing to continue contraception for at least 6 months after&#xD;
             intervention&#xD;
&#xD;
          -  Agrees to participate in follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treated or untreated major depression with psychotic or melancholic features,&#xD;
             schizophrenia, bipolar disorder, delusional disorders, dementias of any type, and&#xD;
             alcoholism or drug abuse (as determined by self-report, Structured Clinical Interview&#xD;
             for DSM disorders (SAGE-SR), and Ham-D)&#xD;
&#xD;
          -  Known allergy to mifepristone, misoprostol, or medicines that contain misoprostol,&#xD;
             such as Cytotec or Arthrotec&#xD;
&#xD;
          -  Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed&#xD;
             approximately 15 drinks per week (with a drink defined as 12 oz. beer, 5oz. wine, or&#xD;
             1.5 oz. distilled spirits) and tobacco use not exceed 20 cigarettes (or equivalent)&#xD;
             per day.&#xD;
&#xD;
          -  Current organ failure (as determined by metabolic panel and self-report)&#xD;
&#xD;
          -  Current treated or untreated rheumatologic and inflammatory disorders, as determined&#xD;
             by medical diagnosis of one or more of the following: osteoarthritis, rheumatoid&#xD;
             arthritis (RA), lupus, spondyloarthropathies -- ankylosing spondylitis (AS) and&#xD;
             psoriatic arthritis (PsA), Sjogren's syndrome, gout, scleroderma, infectious&#xD;
             arthritis, and polymyalgia rheumatic&#xD;
&#xD;
          -  Chronic active infections such as HIV, hepatitis B, and hepatitis C (as determined by&#xD;
             antibody tests)&#xD;
&#xD;
          -  History of organ transplant (self-report)&#xD;
&#xD;
          -  Current primary sleep disorders such as insomnias, sleep related breathing disorders,&#xD;
             etc. (self-report)&#xD;
&#xD;
          -  History of tuberculosis exposure (determined by QuantiFERON-TBÂ® positivity)&#xD;
&#xD;
          -  Any allergic disease (self-report) such as food/drug allergies and allergic asthma&#xD;
&#xD;
          -  Use of medications that could affect immune function (e.g., steroids,&#xD;
             immunosuppressants) or limit the interpretation of the exercise challenge (e.g., beta&#xD;
             blockers) (self-report)&#xD;
&#xD;
          -  Renal insufficiency with serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Hepatic insufficiency (bilirubin &gt;2.5mg/dL or transaminases &gt;5x the ULN) Patients with&#xD;
             Gilberts syndrome are eligible for the study if other liver function tests are normal,&#xD;
             regardless of bilirubin level&#xD;
&#xD;
          -  Currently have no exclusionary diagnoses that could reasonably explain the symptoms of&#xD;
             their fatiguing illness and their severity, using the exclusion criteria best&#xD;
             described in the Ambiguities in case definition paper for Chronic Fatigue Syndrome&#xD;
             (CFS), as described in detail in Reeves, et all 2003, which clarifies exclusionary&#xD;
             conditions.&#xD;
&#xD;
          -  Are scheduled for a surgery within 24 weeks of study enrollment.&#xD;
&#xD;
        Prohibited concomitant or prior therapies:&#xD;
&#xD;
          -  Immunosuppressant drugs, including glucocorticoid taper, topical/inhaled&#xD;
             glucocorticoids&#xD;
&#xD;
          -  Currently on dialysis&#xD;
&#xD;
          -  Recipient of bone marrow or organ transplant&#xD;
&#xD;
          -  Previous or current treatment with angiogenic growth factors, cytokines, gene or stem&#xD;
             cell therapy&#xD;
&#xD;
          -  Participating in another interventional clinical trial of an investigational therapy&#xD;
             within 8 weeks prior to consent to participate in this study, or planning to&#xD;
             participate in another interventional clinical trial of an investigational therapy&#xD;
             within 26 weeks after consent to participate in this study&#xD;
&#xD;
          -  Any herbal medicine&#xD;
&#xD;
          -  Blood thinners&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Klimas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Southeastern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanpreet Cheema, PhD</last_name>
    <phone>(954) 262-2871</phone>
    <email>acheema@nova.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nova Southeastern University</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Klimas, MD</last_name>
      <phone>954-262-2855</phone>
      <email>nklimas@nova.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Klimas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Abreu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gulf War Illness</keyword>
  <keyword>Veterans</keyword>
  <keyword>etanercept</keyword>
  <keyword>mifepristone</keyword>
  <keyword>VA Healthcare</keyword>
  <keyword>TNF</keyword>
  <keyword>Multi-symptom disease</keyword>
  <keyword>Phase I</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data collected during this trial include a wealth of clinical and biomarker data. Due to the small sample size of the trial, the scope of data sharing may be limited because of the risk of compromising participant privacy. For data that can be shared without compromising participant privacy, de-identified limited access data files will be prepared. Additional options to protect privacy of the participants includes altering the data in ways that will not compromise analyses, and requiring outside researchers to adhere to strict confidentiality requirements. All public-release datasets will conform to HIPAA requirements for protecting participant identity.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual Patient Data (IPD) will be released for public sharing after publication of the per-protocol analyses.</ipd_time_frame>
    <ipd_access_criteria>De-identified limited access data sets will be created for public data sharing with investigators proposing analyses related to GWI and related chronic health conditions. To protect the confidentiality and privacy of the subjects, investigators granted access to these data must adhere to strict requirements. These requirements will include, but are not limited to: oversight by an Institutional Review Board (IRB), secure data storage facilities, and agreement not to further release the data. This information will be incorporated into a standard Data Distribution Agreement to which investigators must adhere.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

